AGGF1-primed endothelial progenitor cells alleviate ischaemia-reperfusion injury in diabetic hearts
Abstract A number of cardioprotective pharmacological agents are not effective in diabetic hearts. The role of AGGF1-EPCs therapy in diabetic ischaemia-reperfusion(I/R) injury and the underlying mechanism by which AGGF1 regulates EPCs under hyperglycemia (HG) + hypoxia/reoxygenation (H/R) stress are...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-06190-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849238862579105792 |
|---|---|
| author | Xia Li Suwan Mu Shuting Huang Congcong Dai Yumei Li Jianqiao Li Liang Zhong Miaoling Wei Liuqing Wei Yong Li |
| author_facet | Xia Li Suwan Mu Shuting Huang Congcong Dai Yumei Li Jianqiao Li Liang Zhong Miaoling Wei Liuqing Wei Yong Li |
| author_sort | Xia Li |
| collection | DOAJ |
| description | Abstract A number of cardioprotective pharmacological agents are not effective in diabetic hearts. The role of AGGF1-EPCs therapy in diabetic ischaemia-reperfusion(I/R) injury and the underlying mechanism by which AGGF1 regulates EPCs under hyperglycemia (HG) + hypoxia/reoxygenation (H/R) stress are still unclear. We observed that the damaging effects of HG + H/R on EPCs were abolished by AGGF1. The EPCs implantation therapy successfully restores cardiac functions, inhibits ROS production and fibrosis in diabetic I/R mice. Mechanistically, AGGF1 activates the Nrf2 and induces the activation of downstream antioxidative proteins (HO1, NQO1, and CAT). These data suggest that AGGF1 protein reverses the damaging effects of HG + H/R on EPCs via the antioxidative Nrf2. AGGF1-EPCs therapy is a novel strategy for treating diabetic I/R injury. |
| format | Article |
| id | doaj-art-734aea29b79945caa499d9f1cdbb8607 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-734aea29b79945caa499d9f1cdbb86072025-08-20T04:01:24ZengNature PortfolioScientific Reports2045-23222025-07-0115111210.1038/s41598-025-06190-8AGGF1-primed endothelial progenitor cells alleviate ischaemia-reperfusion injury in diabetic heartsXia Li0Suwan Mu1Shuting Huang2Congcong Dai3Yumei Li4Jianqiao Li5Liang Zhong6Miaoling Wei7Liuqing Wei8Yong Li9Department of Cell Biology and Genetics, School of Intelligent Medicine and Biotechnology, Guilin Medical UniversityDepartment of Cell Biology and Genetics, School of Intelligent Medicine and Biotechnology, Guilin Medical UniversityDepartment of Cell Biology and Genetics, School of Intelligent Medicine and Biotechnology, Guilin Medical UniversityThe Affiliated Hospital of Guilin Medical UniversityThe Second Affiliated Hospital of Guilin Medical UniversityThe Second Affiliated Hospital of Guilin Medical UniversityDepartment of Cell Biology and Genetics, School of Intelligent Medicine and Biotechnology, Guilin Medical UniversityDepartment of Cell Biology and Genetics, School of Intelligent Medicine and Biotechnology, Guilin Medical UniversityDepartment of Cell Biology and Genetics, School of Intelligent Medicine and Biotechnology, Guilin Medical UniversityDepartment of Cell Biology and Genetics, School of Intelligent Medicine and Biotechnology, Guilin Medical UniversityAbstract A number of cardioprotective pharmacological agents are not effective in diabetic hearts. The role of AGGF1-EPCs therapy in diabetic ischaemia-reperfusion(I/R) injury and the underlying mechanism by which AGGF1 regulates EPCs under hyperglycemia (HG) + hypoxia/reoxygenation (H/R) stress are still unclear. We observed that the damaging effects of HG + H/R on EPCs were abolished by AGGF1. The EPCs implantation therapy successfully restores cardiac functions, inhibits ROS production and fibrosis in diabetic I/R mice. Mechanistically, AGGF1 activates the Nrf2 and induces the activation of downstream antioxidative proteins (HO1, NQO1, and CAT). These data suggest that AGGF1 protein reverses the damaging effects of HG + H/R on EPCs via the antioxidative Nrf2. AGGF1-EPCs therapy is a novel strategy for treating diabetic I/R injury.https://doi.org/10.1038/s41598-025-06190-8AGGF1Endothelial progenitor cellsReactive oxygen speciesIschaemia-reperfusion injury |
| spellingShingle | Xia Li Suwan Mu Shuting Huang Congcong Dai Yumei Li Jianqiao Li Liang Zhong Miaoling Wei Liuqing Wei Yong Li AGGF1-primed endothelial progenitor cells alleviate ischaemia-reperfusion injury in diabetic hearts Scientific Reports AGGF1 Endothelial progenitor cells Reactive oxygen species Ischaemia-reperfusion injury |
| title | AGGF1-primed endothelial progenitor cells alleviate ischaemia-reperfusion injury in diabetic hearts |
| title_full | AGGF1-primed endothelial progenitor cells alleviate ischaemia-reperfusion injury in diabetic hearts |
| title_fullStr | AGGF1-primed endothelial progenitor cells alleviate ischaemia-reperfusion injury in diabetic hearts |
| title_full_unstemmed | AGGF1-primed endothelial progenitor cells alleviate ischaemia-reperfusion injury in diabetic hearts |
| title_short | AGGF1-primed endothelial progenitor cells alleviate ischaemia-reperfusion injury in diabetic hearts |
| title_sort | aggf1 primed endothelial progenitor cells alleviate ischaemia reperfusion injury in diabetic hearts |
| topic | AGGF1 Endothelial progenitor cells Reactive oxygen species Ischaemia-reperfusion injury |
| url | https://doi.org/10.1038/s41598-025-06190-8 |
| work_keys_str_mv | AT xiali aggf1primedendothelialprogenitorcellsalleviateischaemiareperfusioninjuryindiabetichearts AT suwanmu aggf1primedendothelialprogenitorcellsalleviateischaemiareperfusioninjuryindiabetichearts AT shutinghuang aggf1primedendothelialprogenitorcellsalleviateischaemiareperfusioninjuryindiabetichearts AT congcongdai aggf1primedendothelialprogenitorcellsalleviateischaemiareperfusioninjuryindiabetichearts AT yumeili aggf1primedendothelialprogenitorcellsalleviateischaemiareperfusioninjuryindiabetichearts AT jianqiaoli aggf1primedendothelialprogenitorcellsalleviateischaemiareperfusioninjuryindiabetichearts AT liangzhong aggf1primedendothelialprogenitorcellsalleviateischaemiareperfusioninjuryindiabetichearts AT miaolingwei aggf1primedendothelialprogenitorcellsalleviateischaemiareperfusioninjuryindiabetichearts AT liuqingwei aggf1primedendothelialprogenitorcellsalleviateischaemiareperfusioninjuryindiabetichearts AT yongli aggf1primedendothelialprogenitorcellsalleviateischaemiareperfusioninjuryindiabetichearts |